SCHEMBL1865619

SCHEMBL1865619

CS(=O)(=O)[O-].CS(=O)(=O)[O-].[Pd+2]

nearest known ligand 0.50

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
CYP3A4 P08684 1/20 0.50
CA1 P00915 1/20 0.42
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.36
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22749162 1.00 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL243288 0.89
SCHEMBL22581617 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL4812594 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL23926540 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL23567016 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL20570539 0.89
SCHEMBL20570963 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL20570026 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1
SCHEMBL17065543 0.89 KDM4E (0.50) KDM4ECYP3A4CA1TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720050-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2026-04-08 EP claimed
CN-119822958-B Method for preparing high-carbon ester compound by combining electrocatalytic and thermocatalytic crude acetylene and two-step cascading device 中国科学技术大学 2025-06-13 CN claimed
CN-119822958-A Method for preparing high-carbon ester compound by combining electrocatalytic and thermocatalytic crude acetylene and two-step cascading device 中国科学技术大学 2025-04-15 CN claimed
WO-2024249672-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2024-12-05 WO claimed
US-12122788-B2 Process of making CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-22 US claimed
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-10-03 US claimed
US-20240300922-A1 PROCESS FOR PREPARING EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2024-09-12 US claimed
EP-4375273-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-29 EP claimed
EP-4359401-A1 PROCESS FOR PREPARING EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-05-01 EP claimed
EP-4313987-A2 PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF KRKA, d.d., Novo mesto (SI) 2024-02-07 EP claimed
WO-2023003014-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE 中外製薬株式会社 2023-01-26 WO claimed
WO-2022271801-A1 PROCESS FOR PREPARING EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO claimed
WO-2022207788-A2 PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF KRKA, D.D., NOVO MESTO (SI) 2022-10-06 WO claimed
WO-2021249877-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES CAMBREX PROFARMACO MILANO S.R.L. (IT) 2021-12-16 WO claimed
US-20190071789-A1 ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES UMICORE GALVANOTECHNIK GMBH (DE) 2019-03-07 US claimed
EP-3365478-A1 ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES Umicore Galvanotechnik GmbH (DE) 2018-08-29 EP claimed
EP-3159435-B1 ADDITIVE FOR SILVER PALLADIUM ALLOY ELECTROLYTES UMICORE GALVANOTECHNIK GMBH (DE) 2018-05-23 EP claimed
WO-2017067985-A1 ADDITIVE FOR SILVER-PALLADIUM ALLOY ELECTROLYTES UMICORE GALVANOTECHNIK GMBH (DE) 2017-04-27 WO claimed
EP-3159435-A1 ADDITIVE FOR SILVER PALLADIUM ALLOY ELECTROLYTES Umicore Galvanotechnik GmbH (DE) 2017-04-26 EP claimed
US-4244739-A ALIPHATIC SULFONIC ACID NOBLE METAL SALTS, FREE OF HYDROCHLORIC ACID METALLIZATION OF NONCONDUCTOR SUPPORTS CAGNASSI ROBERTO 1981-01-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300922-A1 PROCESS FOR PREPARING EGFR INHIBITORS EGFR, ERBB2, ERBB4 KDM4E 3333/4885CYP3A4 2407/4885CA1 3166/4885
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE BRAF, RAF1, NRAS KDM4E 205/4885CYP3A4 1876/4885CA1 4020/4885
US-12122788-B2 Process of making CFTR modulators CFTR, SLC26A4, TMEM109 KDM4E 3960/4885CYP3A4 726/4885CA1 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.